COVID-19 Weekly Epidemiological Update

Data as received by WHO from national authorities, as of 14 March 2021, 10 am CET

In this edition:
• Global overview
• Special focus: Building and maintaining trust - what countries should do to prepare communities for a
COVID-19 vaccine, treatment, or a new test
• Special focus: SARS-CoV-2 variants of concern
• WHO regional overviews
• Key weekly updates
Erratum 18 March 2021: Due to a technical error, data for cases and deaths was inaccurately reported for
some countries/territories/areas in the Weekly Epidemiological Update published on 16 March 2021. They
have been corrected in this version. The change is also reflected in tables, figures and the map.

Global overview
New cases continue to rise globally, increasing by 10% in the past week to over 3 million new reported cases (Table
1). The number of new cases peaked in early January 2021 when there were just under 5 million cases reported in
one week. New cases then declined to just under 2.5 million cases by the week commencing 15 February. However,
for the past three weeks new cases have increased. This week, the Americas and Europe continue to account for
over 80% of new cases and new deaths, with rises in new cases seen in all regions apart from Africa, where
incidence rates decreased by 4%. New deaths on the other hand continue to decline and are now under 60 000,
since peaking in the week commencing 18 January (when there were over 95 000 new deaths in the week). The last
time when there were fewer than 60 000 new weekly deaths was four months ago, in the week commencing 9
November. This week, although new deaths declined globally, they rose in two WHO regions; the Eastern
Mediterranean (by 3%) and the Western Pacific (by 14%).

Figure 1. COVID-19 cases reported weekly by WHO Region, and global deaths, as of 14 March 2021**

**See Annex: Data, table and figure notes

The highest numbers of new cases were reported from Brazil (494 153 new cases; 20% increase), the United
States of America (461 190 new cases; 8% increase), Italy (155 076 new cases; 12% increase), France (150 434
new cases; 5% increase) and India (148 249 new cases; 30% increase).

Table 1. Newly reported and cumulative COVID-19 confirmed cases and deaths, by WHO Region, as of 14 March
2021**
New cases Change in New deaths Change in new
Cumulative Cumulative
WHO Region in last 7 new cases in in last 7 days deaths in last
cases (%) deaths (%)
days (%) last 7 days * (%) 7 days *
1 247 997 52 763 811 30 611 1 268 202
Americas 13% -6%
(41%) (44%) (52%) (48%)
1 225 972 41 033 224 20 809 906 675
Europe 6% -2%
(40%) (34%) (35%) (34%)
199 994 13 884 388 2 141 212 355
South-East Asia 19% -3%
(7%) (12%) (4%) (8%)
Eastern 243 564 6 860 471 2 893 150 193
7% 3%
Mediterranean (8%) (6%) (5%) (6%)
52 929 2 948 478 1 307 74 688
Africa -4% -6%
(2%) (2%) (2%) (3%)
49 553 1 711 830 720 30 357
Western Pacific 19% 14%
(2%) (1%) (1%) (1%)
3 035 703 119 218 587 58 672 2 642 673
Global 10% -4%
(100%) (100%) (100%) (100%)

*Percent change in the number of newly confirmed cases/deaths in past seven days, compared to seven days prior. Regional percentages

rounded to the nearest whole number; global totals may not equal 100%.
**See Annex: Data, table and figure notes

For the latest data and other updates on COVID-19, please see:
• WHO COVID-19 Dashboard
• WHO COVID-19 Weekly Operational Update
Figure 2. COVID-19 cases per 100 000 population reported by countries, territories and areas, 8-14 March 2021**

**See Annex: Data, table and figure notes

Special Focus: Building and maintaining trust - what countries should do to
prepare communities for a COVID-19 vaccine, treatment, or a new test
As we move to the next critical phase of the response, when vaccines and other biomedical tools become
more widely available, building trust and engaging communities remains essential. We have learned from
previous epidemic responses that when communities fully engage and actively participate in the full cycle of
planning, delivery and assessment for new biomedical tools, demand for these tools increases, leading to
widespread and effective uptake and use.

Addressing community concerns

Social-behavioral data tell us that we have much to do in order to build and sustain trust in communities
around the world.

People have concerns over the safety of vaccines and other biomedical tools made with unprecedented speed
and with new technologies. These concerns must be acknowledged and addressed by providing individuals and
communities with actionable, timely and credible health information from trusted sources and by providing
the space and follow-up necessary to work through these concerns with trusted health or community leaders.
Past epidemics have shown us just how quickly and widely individual or community fears can spread if not
dealt with in a timely and comprehensive way.

Recent studies suggest that around 65% of global populations surveyed are willing to be vaccinated with a
COVID-19 vaccine.1 But this has fluctuated over time. The proportion of those likely to accept a COVID-19
vaccine varies significantly between regions and countries and within countries. The barriers to vaccine uptake
are likely to be influenced by a large range of factors.2 These include exposure to misinformation and rumours,
which can negatively impact on vaccine confidence, as well as the role local health care professionals play in
promoting vaccine uptake among their patients and communities.3

As the pandemic becomes protracted, pandemic fatigue is increasing. The growing fatigue, the stress caused
by uncertainty, lower risk perceptions, and reduced trust in government responses, are taking a toll on the
fabric of our communities. This has already led to stigma and discrimination in some settings as well as
protests against public health and social measures in many countries.

This is why since the beginning of the pandemic, WHO has promoted and provided guidance on implementing
a whole-of-society approach to ensure the widest array of stakeholders are actively involved in the
introduction of new biomedical tools, while also supporting communities’ broader trust in their health
systems.

One of the ways WHO is supporting countries strengthen their engagement and empowerment strategies is
through the publication of the 10 Steps to Community Readiness – What countries should do to prepare
communities for a COVID-19 vaccine, treatment, or new test.

This is a new tool, developed by WHO, UNICEF, IFRC and the Global Outbreak and Alert Response Network
(GOARN) through the Risk Communication and Community Engagement (RCCE) Collective Service (a new
partnership launched in June 2020), to strengthen coordination and quality of practice for the COVID-19
pandemic response.

1 Johns Hopkins University, WHO, GOARN, Facebook, MIT (2021) KAP COVID-19 - Vaccine acceptance around the world.
https://ccp.jhu.edu/kap-covid/vaccine-acceptance
2 Anthrologica (2020) Literature analysis: norms and practices relevant to COVID-19 in the Middle East and North Africa Region.
3 PERC (2020) Responding to COVID-19 in Africa: using data to find a balance Part II. https://preventepidemics.org/covid19/perc/
Figure 3: 10 Steps to Community Readiness

The tool is built around the recognition that the empowerment of people and communities is not an abstract
idea, and there are concrete and measurable steps that can be taken to ensure citizens are engaged and ready
to support new biomedical tools.

Though communication needs may be slightly different for each step, the principles that promote their safe
and successful introduction remain the same.

The steps build on well-established RCCE principles that put communities at the heart of the roll-out of new
vaccines, treatments, and tests, and promote trust – the critical ingredient for all community action.

With the imminent arrival of new biomedical tools, investments in coordinated and proactive community
engagement approaches, such as the 10 Steps to Community Readiness, are now needed more than ever.
These approaches not only support the widest possible uptake of new tools but also support the continued
maintenance of protective behaviours, such as mask wearing and physical distancing.

Additional resources:

• Tools guidance and job aids to support implementing each of the 10 steps that lead to community readiness
• Ways the RCCE Collective Service supporting regions and countries
• Guidance on how to ensure people centered and community led approaches underpin the COVID-19 response
Special Focus: Update on SARS-CoV-2 Variants of Concern
WHO, in collaboration with national authorities, institutions and researchers, continues to monitor the public
health events associated with SARS-CoV-2 variants. Further information on the background of the variants of
concern (VOCs) is available in previously published editions of the Weekly Epidemiological Update. Here we
provide an update on the geographical distribution of the three VOCs, considered as such by WHO and as
reported by countries, territories and areas (hereafter countries) as of 16 March 2021; and emerging variants
of interest (VOIs).

As surveillance activities, including systematic genomic sequencing, are strengthened at local and national
levels to detect cases infected with SARS-CoV-2 variants, the number of countries reporting VOCs has
continued to increase (Table 2, Figures 4-6, Annex 2). This information should be interpreted with due
consideration of limitations of ongoing surveillance, including but not limited to differences between
countries in sequencing capacity and which samples are prioritized for sequencing. WHO continues to
advocate for strengthening surveillance and sequencing capacity, and a systematic approach to provide a
representative indication of the extent of transmission of SARS-CoV-2 variants; based on the local
epidemiological situation and capacity, and the detection of unusual events.

Table 2: Overview of emerging information on key variants of concern, as of 16 March 2021*

Nextstrain clade 20I/501Y.V1 20H/501Y.V2† 20J/501Y.V3
PANGO lineage B.1.1.7 B.1.351 B.1.1.28.1, alias P.1†
GISAID clade GR GH GR
†
Alternate names VOC 202012/01 VOC 202012/02 -
First detected by United Kingdom South Africa Brazil / Japan
Earliest sample date 20 September 2020 Early August 2020 December 2020
Key spike mutations H69/V70 deletion; Y144 L242/A243/L244 K417T, E484K; N501Y
deletion; N501Y; A570D; deletion; K417N; E484K;
P681H N501Y
Key mutation in common S106/G107/F108 deletion in Non-Structural Protein 6 (NSP6)
Countries reporting cases 118 (7) 64 (6) 38 (6)
(newly reported in last
week)**
†While work is ongoing to establish standardized nomenclature for key variants, these are the names by which WHO will refer to them in this
publication. **Includes official and unofficial reports of VOCs detections in countries among either travellers (imported cases only) or
community samples (local transmission).

Figure 4. Countries, territories and areas reporting SARS-CoV-2 VOC 202012/01 as of 16 March 2021
Figure 5. Countries, territories and areas reporting SARS-CoV-2 variant 501Y.V2 as of 16 March 2021

Figure 6. Countries, territories and areas reporting SARS-CoV-2 variant P.1 as of 16 March 2021

Emerging variants of interest (VOIs)

All viruses, including SARS-CoV-2, change over time resulting in the emergence of new variants, most without
a direct benefit to the virus or other public health impacts. WHO, in collaboration with national authorities,
institutions and researchers, routinely assesses if variants of SARS-CoV-2 result in changes in transmissibility,
clinical presentation and severity, or if they impact on public health and social measures (PHSM). Systems
have been established to detect “signals” of potential variants of interest or concern, as well as unusual
events potentially associated with a variant, and assess these based on the risk posed to global public health
(see also working definitions). Such signals are currently under assessment, and as new variants of interest
VOIs or VOCs are determined, WHO is committed to highlighting these to support prioritization for further
monitoring and assessment.
A SARS-CoV-2 variant, labelled CAL.20C/L452R (based upon the NextStrain subclade and key mutation),
spanning PANGO lineages B.1.427 and B.1.429, has been designated as a VOI by WHO based on recent
assessments and emerging evidence. This variant is characterized by a combination of three mutations in the
receptor binding domain (RBD), namely S13I, W152C, L452R, of which the focus is on the L452R mutation. It
was first detected during a local increase in COVID-19 cases in California, United States of America in June
2020. Surveillance has shown that it has since contributed to a substantive proportion of local COVID-19
cases in California, and has been detected in all US states and at least 26 other countries to date1-4. Outside
of the US, reported detections of this VOI are currently limited to a relatively low number of sequences,
suggesting it has not yet resulted in widespread disease in other countries.

The assessment as a VOI follows preliminary, emerging evidence that this variant may be associated with
phenotypic impacts which may pose an increased public health risk and COVID-19 control measures
compared to other variants. This includes a possible increase in transmissibility,1 mixed findings on
potentially higher infectivity (based on PCR cycle thresholds as a proxy),1,5,6 and a slight reduction in
neutralization for sera from recovered patients clinically diagnosed with COVID-19 and in vaccine
recipients.1,7 The L452R mutation has been associated with a reduction in neutralization of monoclonal
antibodies but further investigations are ongoing8,9. The impact of this variant on disease severity is under
investigation. These are preliminary findings, include non-peer review studies, and require further
investigations. WHO is working with US Centers for Disease Control and Prevention (CDC) and the WHO Virus
Evolution Working Group to further assess this VOI.

WHO recommendations and working definitions of VOI and VOC

The potential for virus mutation increases with the frequency of human and animal infections. Therefore,
reducing transmission of all circulating SARS-CoV-2 viruses and variants by using established disease control
methods, are critical aspects of the global strategy to reduce the occurrence of mutations that have negative
public health implications. PHSM and infection prevention and control measures inside and outside of health
facilities remain critically important to curb the spread of SARS-CoV-2, including newly reported variants.
Evidence from multiple countries with extensive transmission of VOCs has indicated that the implementation
of physical distancing and other PHSM, as well as infection prevention and control (IPC) measures in health
facilities, has been effective in reducing COVID-19 case incidence, which has led to a reduction in
hospitalizations and deaths among COVID-19 patients. Findings from new studies evaluating transmission,
severity and impact on medical countermeasures will continue to help inform PHSM and IPC measures
employed by Member States. National and local authorities are encouraged to continue strengthening
existing PHSM, IPC and disease control activities, including epidemiological surveillance, strategic testing, and
systematic sequencing of SARS-CoV-2 where feasible.

On 25 February 2021, proposed working definitions of SARS-CoV-2 Variants of Interest and Variants of
Concern were published. As SARS-CoV-2 is continuously evolving, and new signals of potential VOIs and VOCs
are frequently detected, WHO aims to assess potential VOCs based on the risk posed to global public health.
National authorities may choose to designate other variants of local interest/concern as every local
situation is unique, with different variants circulating, requiring surveillance and response systems to adapt
to their local epidemiological situation.

If potential VOIs or VOCs are detected, Member States are requested to inform WHO through established
WHO Country or Regional Office reporting channels, submit genome sequences to publicly available
databases (e.g., GISAID), and perform field and laboratory investigations (where appropriate) to improve
understanding of potential impacts.

Additional resources
• Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health
• Considerations for implementing and adjusting PHSM in the context of COVID-19
• Proposed working definitions of SARS-CoV-2 Variants of Interest and Variants of Concern
• Disease Outbreak News on SARS-CoV-2 Variants, 31 December 2020
References
1. Deng X, et al. Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a
L452R spike protein mutation. medRxiv. Available
at: https://www.medrxiv.org/content/10.1101/2021.03.07.21252647v1 (preprint)
2. Latif AA, et al. B.1.427 Lineage Report. Outbreak.info. Available at: https://outbreak.info/situation-
reports?pango=B.1.427&country=United%20States&division=California&selected=California&selectedType=division
3. Latif AA, et al. B.1.429 Lineage Report. Outbreak.info. Available at: https://outbreak.info/situation-
reports?pango=B.1.429&country=United%20States&division=California&selected=California&selectedType=division
4. O’Toole A et al. Pangolin: lineage assignment in an emerging pandemic as an epidemiological tool. Available at: https://cov-lineages.org/
5. Drew RJ et al. The importance of cycle threshold values in interpreting molecular tests for SARS-CoV-2. Diagn Microbiol Infect Dis. 2020
Nov;98(3):115130. doi: 10.1016/j.diagmicrobio.2020.115130.
6. Peng J et al. Estimation of secondary household attack rates for emergent SARS-CoV-2 variants detected by genomic surveillance at a
community-based testing site in San Francisco. medRxiv. Available
at: https://www.medrxiv.org/content/10.1101/2021.03.01.21252705v1.full (preprint)
7. Garcia-Beltran WF et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. medRxiv. Available
at: https://www.medrxiv.org/content/10.1101/2021.02.14.21251704v2 (preprint)
8. Li Q et al. The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity. Cell 2020 Sep;182(5):1284-1294. doi:
10.1016/j.cell.2020.07.012.
9. Starr TN et al. Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-
CoV016. bioRxiv. Available at: https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1.full (preprint)
WHO regional overviews Region of the Americas
African Region
The Region of the Americas reported over 1.2 million new cases and over 30
The African Region reported under 53 000 new cases and just over 1300 new 000 new deaths, a 13% increase and a 6% decrease respectively compared to
deaths, a 4% and a 6% decrease respectively compared to the previous week. the previous week. Deaths continued to decrease for the second consecutive
The decreasing trend in deaths has been observed since early February 2021. week. The highest numbers of new cases were reported from Brazil (494 153
The highest numbers of new cases were reported from Ethiopia (9025 new new cases; 232.5 new cases per 100 000; a 20% increase), the United States of
cases; 7.9 new cases per 100 000 population; a 29% increase), South Africa America (461 190 new cases; 139.3 new cases per 100 000; an 8% increase),
(8208 new cases; 13.8 new cases per 100 000; a 3% increase), and Kenya (4443 and Argentina (45 311 new cases; 100.3 new cases per 100 000; a 7% increase).The
new cases; 8.3 new cases per 100 000; a 64% increase). highest numbers of new deaths were reported from Brazil (12 335 new deaths;
5.8 new deaths per 100 000; a 24% increase), the United States of America
The highest numbers of new deaths were reported from South Africa (614 new (9381 new deaths; 2.8 new deaths per 100 000; a 24% decrease), and Mexico
deaths; 1.0 new deaths per 100 000; a 13% decrease), Ethiopia (120 new (4273 new deaths; 3.3 new deaths per 100 000; a 16% decrease). These three
deaths; 0.1 new deaths per 100 000; an 82% increase), and Botswana (65 new countries accounted for 85% of deaths reported in the Americas this week.
deaths; 2.8 new deaths per 100 000; a 33% increase).
Eastern Mediterranean Region European Region
The European Region reported over 1.2 million new cases, and just over 20 000
The Eastern Mediterranean Region reported over 243 000 new cases and under
new deaths, a 6% increase, and a 2% decrease respectively compared to the
2900 new deaths, a 7% and a 3% increase respectively compared to the
previous week. Cases in the Region have been steadily increasing over the past
previous week. New weekly cases have increased for the past five weeks and
three weeks while trends in new deaths have been consistently declining for
deaths have increased for the past three weeks. The highest numbers of new
the past eight weeks. The highest numbers of new cases were reported from
cases were reported from the Islamic Republic of Iran (57 678 new cases; 68.7
Italy (155 076 new cases; 256.5 new cases per 100 000; a 12% increase), France
new cases per 100 000; a 1% decrease), Jordan (47 585 new cases; 466.4 new
(150 434 new cases; 230.5 new cases per 100 000; a 5% increase) and Poland
cases per 100 000; a 36% increase), and Iraq (31 129 new cases; 77.4 new cases
(111 718 new cases; 295.2 new cases per 100 000; a 27% increase).
per 100 000; a 1% increase).
The highest numbers of new deaths were reported from the Russian
The highest numbers of new deaths were reported from the Islamic Republic
Federation (2990 new deaths; 2.0 new deaths per 100 000; similar to the
of Iran (548 new deaths; 0.7 new deaths per 100 000; an 11% decrease), Jordan
previous week), Italy (2303 new deaths; 3.8 new deaths per 100 000; an 11%
(385 new deaths; 3.8 new deaths per 100 000; a 71% increase), and Lebanon
increase), and Poland (1893 new deaths; 5.0 new deaths per 100 000; a 25%
(321 new deaths; 4.7 new deaths per 100 000; an 11% decrease).
increase).
South-East Asia Region Western Pacific Region
The South-East Asia Region reported just under 200 000 new cases and just The Western Pacific Region reported under 50 000 new cases and over 700
over 2100 new deaths, a 19% increase and a 3% decrease respectively new deaths, a 19% and a 14% increase respectively compared to the previous
compared to the previous week. The highest numbers of new cases were week. This is the first time in seven weeks that an increase in new cases has
reported from India (148 249 new cases; 10.7 new cases per 100 000; a 30% been reported with new deaths also showing an uptick. The highest numbers
increase), Indonesia (40 905 new cases; 15.0 new cases per 100 000; a 9% of new cases were reported from the Philippines (25 473 new cases; 23.2 new
decrease), and Bangladesh (6512 new cases; 4.0 new cases per 100 000; a 67% cases per 100 000; a 51% increase), Malaysia (10 632 new cases; 32.8 new cases
increase). per 100 000; a 21% decrease), and Japan (7917 new cases; 6.3 new cases per
100 000; a 10% increase).
The highest numbers of new deaths were reported from Indonesia (1175 new
deaths; 0.4 new deaths per 100 000; similar to the previous week), India (851 The highest numbers of new deaths were reported from Japan (333 new
new deaths; 0.1 new deaths per 100 000; a 21% increase), and Bangladesh (76 deaths; 0.3 new deaths per 100 000; a 9% decrease), the Philippines (301 new
new deaths; <0.1 new deaths per 100 000; a 49% increase). deaths; 0.3 new deaths per 100 000; a 71% increase), and Malaysia (40 new
deaths; 0.1 new deaths per 100 000; an 11% decrease).
Key weekly updates
WHO Director-General's key message
Opening remarks at the media briefing on COVID-19 – 12 March 2021: The inequitable distribution of vaccines
remains the biggest threat to ending the pandemic and driving a global recovery.

International Women’s Day: Women and COVID-19

• WHO signs MoU with Women in Global Health on International Women’s Day
• Devastatingly pervasive: 1 in 3 women globally experience violence
• Women scientists capture public attention as COVID-19 rages across the world

COVID-19 Vaccines
• Waive COVID vaccine patents to put world on war footing
• WHO adds Janssen vaccine to list of safe and effective emergency tools against COVID-19
• GACVS COVID-19 Vaccine Safety subcommittee meeting to review reports on influenza-like illness in
individuals vaccinated with COVID-19 vaccines

COVID-19 Solidarity Response Fund

• COVID-19 Solidarity Response Fund marks first anniversary and appeals for continued support

ACT Accelerator strategy and budget

• ACT-Accelerator releases prioritised strategy and budget for 2021 to change the course of the evolving COVID-
19 pandemic

Technical guidance and other resources

• Technical guidance
• WHO Coronavirus Disease (COVID-19) Dashboard
• Weekly COVID-19 Operational Updates
• WHO COVID-19 case definitions
• COVID-19 Supply Chain Inter-Agency Coordination Cell Weekly Situational Update
• Research and Development
• Online courses on COVID-19 in official UN languages and in additional national languages
• The Strategic Preparedness and Response Plan (SPRP) outlining the support the international community can
provide to all countries to prepare and respond to the virus
• Updates from WHO regions:
o African Region
o Region of the Americas
o Eastern Mediterranean Region
o South-East Asia Region
o European Region
o Western Pacific Region
• Recommendations and advice for the public:
o Protect yourself
o Questions and answers
o Travel advice
• EPI-WIN: tailored information for individuals, organizations and communities
Annex
Annex 1. COVID-19 confirmed cases and deaths reported in the last seven days by countries, territories and areas, and WHO Region, as of 14 March 2021**
Cumulative cases Cumulative
New cases New
Reporting Cumulative per 100 Cumulative deaths per 100 Transmission
in last 7 deaths in
Country/Territory/Areai cases thousand deaths thousand classificationii
days last 7 days
population population
Africa 52 929 2 948 478 262.8 1 307 74 688 6.7
Ethiopia 9 025 174 054 151.4 120 2 540 2.2 Community transmission
South Africa 8 208 1 528 414 2 577.0 614 51 261 86.4 Community transmission
Kenya 4 443 112 805 209.8 34 1 908 3.5 Community transmission
Cameroon 3 274 38 988 146.9 37 588 2.2 Community transmission
Zambia 2 463 84 474 459.5 37 1 153 6.3 Community transmission
Botswana 2 440 34 098 1 450.0 65 424 18.0 Community transmission
Côte d’Ivoire 2 369 37 304 141.4 11 211 0.8 Community transmission
Nigeria 2 300 160 537 77.9 49 2 013 1.0 Community transmission
Mozambique 2 165 64 296 205.7 36 722 2.3 Community transmission
Ghana 1 670 87 762 282.4 45 685 2.2 Community transmission
Madagascar 1 201 21 356 77.1 26 326 1.2 Community transmission
Algeria 1 169 115 273 262.9 27 3 037 6.9 Community transmission
Namibia 1 148 41 025 1 614.6 21 458 18.0 Community transmission
Gabon 1 143 16 660 748.5 6 96 4.3 Community transmission
Senegal 1 094 36 726 219.3 47 955 5.7 Community transmission
Guinea 1 052 17 592 134.0 9 102 0.8 Community transmission
Rwanda 800 20 226 156.2 9 276 2.1 Community transmission
South Sudan 752 9 429 84.2 2 104 0.9 Community transmission
Togo 528 8 049 97.2 3 93 1.1 Community transmission
Democratic Republic of the Congo 469 26 937 30.1 5 717 0.8 Community transmission
Benin 430 6 501 53.6 6 81 0.7 Community transmission
Malawi 391 32 789 171.4 15 1 082 5.7 Community transmission
 Cumulative cases Cumulative
New cases New
Reporting Cumulative per 100 Cumulative deaths per 100 Transmission
in last 7 deaths in
Country/Territory/Areai cases thousand deaths thousand classificationii
days last 7 days
population population
Cabo Verde 311 16 035 2 884.1 4 156 28.1 Community transmission
Mali 302 8 862 43.8 2 360 1.8 Community transmission
Angola 268 21 323 64.9 8 520 1.6 Community transmission
Seychelles 252 3 202 3 255.8 1 15 15.3 Community transmission
Equatorial Guinea 233 6 562 467.7 2 98 7.0 Community transmission
Zimbabwe 211 36 471 245.4 16 1 501 10.1 Community transmission
Burkina Faso 197 12 350 59.1 1 144 0.7 Community transmission
Gambia 180 4 939 204.4 1 153 6.3 Community transmission
Congo 150 9 329 169.1 0 131 2.4 Community transmission
Sao Tome and Principe 140 2 078 948.2 1 32 14.6 Community transmission
Chad 127 4 288 26.1 13 153 0.9 Community transmission
Guinea-Bissau 124 3 436 174.6 3 52 2.6 Community transmission
Burundi 122 2 441 20.5 0 3 0.0 Community transmission
Niger 117 4 857 20.1 9 181 0.7 Community transmission
Mauritania 101 17 410 374.4 0 442 9.5 Community transmission
Eritrea 94 3 038 85.7 0 7 0.2 Community transmission
Uganda 92 40 544 88.6 0 334 0.7 Community transmission
Mauritius 71 691 54.3 0 10 0.8 Clusters of cases
Eswatini 61 17 234 1 485.5 3 661 57.0 Community transmission
Comoros 32 3 623 416.6 1 146 16.8 Community transmission
Sierra Leone 19 3 937 49.4 0 79 1.0 Community transmission
Lesotho 7 10 530 491.5 2 309 14.4 Community transmission
Liberia 6 2 030 40.1 0 85 1.7 Community transmission
Central African Republic 0 5 021 104.0 0 63 1.3 Community transmission
United Republic of Tanzania 0 509 0.9 0 21 0.0 Pending
 Cumulative cases Cumulative
New cases New
Reporting Cumulative per 100 Cumulative deaths per 100 Transmission
in last 7 deaths in
Country/Territory/Areai cases thousand deaths thousand classificationii
days last 7 days
population population
Territoriesiii
Réunion 676 13 801 1 541.5 12 71 7.9 Community transmission
Mayotte 502 18 642 6 833.2 4 129 47.3 Community transmission
Americas 1 247 997 52 763 811 5 158.9 30 611 1 268 202 124.0
Brazil 494 153 11 363 380 5 346.0 12 335 275 105 129.4 Community transmission
United States of America 461 190 29 063 401 8 780.4 9 381 528 456 159.7 Community transmission
Argentina 45 311 2 192 025 4 850.1 776 53 646 118.7 Community transmission
Peru 44 316 1 402 610 4 254.0 1 173 48 664 147.6 Community transmission
Mexico 38 466 2 157 771 1 673.6 4 273 193 851 150.4 Community transmission
Chile 34 896 885 379 4 631.6 566 21 574 112.9 Community transmission
Colombia 25 035 2 294 617 4 509.6 650 60 950 119.8 Community transmission
Canada 21 472 903 233 2 393.2 212 22 404 59.4 Community transmission
Paraguay 11 782 177 593 2 489.9 158 3 436 48.2 Community transmission
Ecuador 7 723 300 666 1 704.2 195 16 215 91.9 Community transmission
Uruguay 7 145 69 074 1 988.5 52 689 19.8 Community transmission
Cuba 5 723 60 558 534.7 22 366 3.2 Community transmission
Bolivia (Plurinational State of) 5 027 258 324 2 213.0 114 11 903 102.0 Community transmission
Jamaica 4 609 29 912 1 010.1 38 484 16.3 Community transmission
Guatemala 4 342 182 679 1 019.7 96 6 563 36.6 Community transmission
Honduras 4 148 177 168 1 788.7 78 4 325 43.7 Community transmission
Panama 3 483 347 226 8 047.4 74 5 981 138.6 Community transmission

Venezuela (Bolivarian Republic of) 3 430 144 786 509.2 51 1 422 5.0 Community transmission

Dominican Republic 2 956 245 616 2 264.2 51 3 213 29.6 Community transmission
Costa Rica 2 453 209 093 4 104.6 29 2 862 56.2 Community transmission
 Cumulative cases Cumulative
New cases New
Reporting Cumulative per 100 Cumulative deaths per 100 Transmission
in last 7 deaths in
Country/Territory/Areai cases thousand deaths thousand classificationii
days last 7 days
population population
El Salvador 1 286 62 086 957.2 51 1 945 30.0 Community transmission
Guyana 340 9 069 1 153.0 6 206 26.2 Clusters of cases
Barbados 174 3 391 1 180.0 0 37 12.9 Community transmission
Antigua and Barbuda 149 962 982.3 6 27 27.6 Clusters of cases
Saint Lucia 146 3 989 2 172.3 5 48 26.1 Community transmission
Bahamas 106 8 722 2 218.0 3 185 47.0 Clusters of cases
Haiti 96 12 632 110.8 0 250 2.2 Community transmission
Suriname 46 9 012 1 536.2 1 176 30.0 Clusters of cases
Nicaragua 40 5 216 78.7 1 175 2.6 Community transmission
Trinidad and Tobago 40 7 769 555.1 1 140 10.0 Community transmission
Belize 35 12 370 3 110.9 1 316 79.5 Community transmission
Saint Vincent and the Grenadines 22 1 680 1 514.3 0 8 7.2 Community transmission
Dominica 12 156 216.7 0 0 0.0 Clusters of cases
Saint Kitts and Nevis 2 43 80.8 0 0 0.0 Sporadic cases
Grenada 0 151 134.2 0 1 0.9 Sporadic cases
Territoriesiii
Saint Barthélemy 10 779 725 7 334.3 169 1 10.1 Clusters of cases
Curaçao 4 915 4 751 2 895.3 22 22 13.4 Community transmission
Puerto Rico 1 240 102 567 3 585.2 18 2 077 72.6 Community transmission
Guadeloupe 267 10 725 2 680.4 0 168 42.0 Community transmission
Aruba 263 8 272 7 747.8 2 77 72.1 Community transmission
Martinique 151 7 037 1 875.2 0 47 12.5 Community transmission
French Guiana 71 16 764 5 612.7 0 87 29.1 Community transmission
United States Virgin Islands 53 2 767 2 649.7 0 25 23.9 Community transmission
Saint Martin 31 1 612 4 169.8 0 12 31.0 Community transmission
 Cumulative cases Cumulative
New cases New
Reporting Cumulative per 100 Cumulative deaths per 100 Transmission
in last 7 deaths in
Country/Territory/Areai cases thousand deaths thousand classificationii
days last 7 days
population population
Turks and Caicos Islands 28 2 200 5 682.1 1 15 38.7 Clusters of cases
Cayman Islands 17 468 712.1 0 2 3.0 Sporadic cases
Bermuda 13 735 1 180.3 0 12 19.3 Sporadic cases
Sint Maarten 12 2 078 4 845.9 0 27 63.0 Community transmission
Anguilla 3 21 140.0 0 0 0.0 Sporadic cases
Bonaire 0 455 2 175.5 0 5 23.9 Community transmission
British Virgin Islands 0 154 509.3 0 1 3.3 Clusters of cases
Falkland Islands (Malvinas) 0 51 1 464.3 0 0 0.0 No cases
Montserrat 0 20 400.1 0 1 20.0 Sporadic cases
Saba 0 6 310.4 0 0 0.0 No cases
Saint Pierre and Miquelon 0 24 414.2 0 0 0.0 No cases
Sint Eustatius 0 20 637.1 0 0 0.0 No cases
Eastern Mediterranean 243 564 6 860 471 938.7 2 893 150 193 20.6
Iran (Islamic Republic of) 57 678 1 739 360 2 070.8 548 61 142 72.8 Community transmission
Jordan 47 585 469 000 4 596.6 385 5 285 51.8 Community transmission
Iraq 31 129 754 318 1 875.4 171 13 719 34.1 Community transmission
Lebanon 22 151 415 362 6 085.5 321 5 334 78.1 Community transmission
United Arab Emirates 16 169 424 405 4 291.1 78 1 388 14.0 Community transmission
Pakistan 13 808 602 536 272.8 310 13 476 6.1 Community transmission
Kuwait 9 032 208 460 4 881.3 45 1 165 27.3 Community transmission
Libya 6 161 143 643 2 090.5 112 2 348 34.2 Community transmission
Egypt 4 358 190 280 185.9 302 11 256 11.0 Clusters of cases
Bahrain 4 278 130 404 7 663.7 12 481 28.3 Clusters of cases
Tunisia 4 229 241 257 2 041.3 192 8 359 70.7 Community transmission
Qatar 3 292 169 767 5 892.5 3 265 9.2 Community transmission
 Cumulative cases Cumulative
New cases New
Reporting Cumulative per 100 Cumulative deaths per 100 Transmission
in last 7 deaths in
Country/Territory/Areai cases thousand deaths thousand classificationii
days last 7 days
population population
Morocco 2 658 488 632 1 323.8 42 8 718 23.6 Clusters of cases
Saudi Arabia 2 585 382 059 1 097.4 39 6 563 18.9 Sporadic cases
Oman 2 361 145 257 2 844.5 17 1 600 31.3 Community transmission
Somalia 905 8 946 56.3 55 349 2.2 Community transmission
Syrian Arab Republic 476 16 401 93.7 36 1 094 6.3 Community transmission
Yemen 327 2 775 9.3 33 684 2.3 Community transmission
Sudan 316 30 923 70.5 42 1 953 4.5 Community transmission
Afghanistan 138 55 985 143.8 8 2 457 6.3 Clusters of cases
Djibouti 118 6 252 632.8 0 63 6.4 Community transmission
Territoriesiii
occupied Palestinian territory 13 810 234 449 4 595.8 142 2 494 48.9 Community transmission
Europe 1 225 972 41 033 224 4 396.1 20 809 906 675 97.1
Italy 155 076 3 201 838 5 295.6 2 303 101 881 168.5 Clusters of cases
France 150 434 3 965 264 6 074.8 1 660 89 632 137.3 Community transmission
Poland 111 718 1 906 632 5 037.8 1 893 47 178 124.7 Community transmission
Turkey 96 782 2 866 012 3 398.2 456 29 421 34.9 Community transmission
Czechia 77 747 1 399 078 13 064.5 1 509 23 226 216.9 Community transmission
Germany 69 063 2 569 245 3 066.5 1 471 73 371 87.6 Community transmission
Russian Federation 67 832 4 390 608 3 008.6 2 990 92 090 63.1 Clusters of cases
Ukraine 59 528 1 460 756 3 340.1 1 281 28 303 64.7 Community transmission
Hungary 50 473 516 490 5 346.5 1 079 16 952 175.5 Community transmission
The United Kingdom 40 477 4 253 824 6 266.1 1 045 125 464 184.8 Community transmission
Netherlands 35 811 1 151 180 6 718.3 243 16 045 93.6 Community transmission
Romania 30 331 855 326 4 446.1 585 21 439 111.4 Community transmission
Serbia 29 654 512 051 7 353.1 152 4 694 67.4 Community transmission
 Cumulative cases Cumulative
New cases New
Reporting Cumulative per 100 Cumulative deaths per 100 Transmission
in last 7 deaths in
Country/Territory/Areai cases thousand deaths thousand classificationii
days last 7 days
population population
Sweden 23 431 712 527 7 055.2 30 13 146 130.2 Community transmission
Belgium 19 397 808 283 6 974.2 167 22 441 193.6 Community transmission
Austria 18 468 488 007 5 418.4 123 8 652 96.1 Community transmission
Spain 18 078 3 183 704 6 809.4 308 72 258 154.5 Community transmission
Bulgaria 18 067 277 878 3 999.1 641 11 234 161.7 Clusters of cases
Greece 15 543 219 521 2 106.1 333 7 038 67.5 Community transmission
Slovakia 14 113 337 503 6 181.8 692 8 528 156.2 Clusters of cases
Estonia 9 804 84 807 6 393.1 66 719 54.2 Clusters of cases
Republic of Moldova 9 105 203 710 5 049.9 203 4 294 106.4 Community transmission
Israel 7 903 806 257 9 314.9 62 5 925 68.5 Community transmission
Belarus 6 896 301 328 3 188.9 58 2 087 22.1 Community transmission
Bosnia and Herzegovina 6 720 143 218 4 365.3 241 5 488 167.3 Community transmission
Switzerland 5 937 567 967 6 562.6 37 9 359 108.1 Community transmission
Denmark 5 592 219 918 3 796.8 13 2 390 41.3 Community transmission
North Macedonia 5 275 112 107 5 381.0 115 3 300 158.4 Community transmission
Kazakhstan 5 194 273 521 1 456.7 67 3 456 18.4 Clusters of cases
Slovenia 4 765 199 855 9 613.3 26 4 218 202.9 Clusters of cases
Albania 4 735 116 813 4 059.1 112 2 030 70.5 Clusters of cases
Norway 4 547 78 040 1 439.5 7 639 11.8 Community transmission
Croatia 4 531 251 045 6 115.2 87 5 677 138.3 Community transmission
Portugal 4 304 813 716 7 980.2 157 16 669 163.5 Clusters of cases
Finland 3 943 66 006 1 191.3 19 786 14.2 Community transmission
Armenia 3 706 178 385 6 019.9 34 3 255 109.8 Community transmission
Ireland 3 659 226 358 4 584.2 115 4 534 91.8 Community transmission
Montenegro 3 502 83 690 13 325.0 55 1 122 178.6 Clusters of cases
 Cumulative cases Cumulative
New cases New
Reporting Cumulative per 100 Cumulative deaths per 100 Transmission
in last 7 deaths in
Country/Territory/Areai cases thousand deaths thousand classificationii
days last 7 days
population population
Latvia 3 475 93 484 4 956.2 70 1 757 93.2 Community transmission
Azerbaijan 3 327 239 692 2 364.0 38 3 276 32.3 Clusters of cases
Lithuania 3 171 205 385 7 544.6 68 3 396 124.7 Community transmission
Cyprus 2 702 39 277 3 253.1 6 238 19.7 Clusters of cases
Georgia 2 138 274 989 6 893.4 72 3 648 91.4 Community transmission
Malta 2 051 26 267 5 948.9 21 350 79.3 Clusters of cases
Luxembourg 1 194 57 700 9 217.6 31 688 109.9 Community transmission
Uzbekistan 391 80 567 240.7 0 622 1.9 Clusters of cases
Kyrgyzstan 300 86 850 1 331.2 10 1 481 22.7 Clusters of cases
Andorra 209 11 228 14 531.8 0 112 145.0 Community transmission
San Marino 204 4 126 12 157.5 1 77 226.9 Community transmission
Monaco 88 2 106 5 366.4 1 27 68.8 Sporadic cases
Iceland 13 6 072 1 779.4 0 29 8.5 Community transmission
Liechtenstein 10 2 678 7 022.1 0 54 141.6 Sporadic cases
Holy See 0 26 3 213.8 0 0 0.0 Sporadic cases
Tajikistan 0 13 714 143.8 0 91 1.0 Pending
Territoriesiii
Kosovo [1] 4 048 76 505 4 112.3 56 1 686 90.6 Community transmission
Isle of Man 486 1 092 1 284.2 0 25 29.4 No cases
Gibraltar 19 4 263 12 653.2 0 93 276.0 Clusters of cases
Faroe Islands 3 661 1 352.7 0 1 2.0 Sporadic cases
Jersey 2 3 222 2 961.4 0 69 63.4 Community transmission
Greenland 0 31 54.6 0 0 0.0 No cases
Guernsey 0 821 1 299.1 0 14 22.2 Community transmission
South-East Asia 199 994 13 884 388 686.9 2 141 212 355 10.5
 Cumulative cases Cumulative
New cases New
Reporting Cumulative per 100 Cumulative deaths per 100 Transmission
in last 7 deaths in
Country/Territory/Areai cases thousand deaths thousand classificationii
days last 7 days
population population
India 148 249 11 359 048 823.1 851 158 607 11.5 Clusters of cases
Indonesia 40 905 1 414 741 517.2 1 175 38 329 14.0 Community transmission
Bangladesh 6 512 556 236 337.7 76 8 527 5.2 Community transmission
Sri Lanka 2 264 87 600 409.1 33 526 2.5 Clusters of cases
Maldives 813 21 476 3 973.0 0 64 11.8 Clusters of cases
Thailand 557 26 927 38.6 1 86 0.1 Clusters of cases
Nepal 523 275 178 944.4 4 3 014 10.3 Clusters of cases
Myanmar 113 142 136 261.2 1 3 201 5.9 Clusters of cases
Timor-Leste 58 178 13.5 0 0 0.0 Clusters of cases
Bhutan 0 868 112.5 0 1 0.1 Sporadic cases
Western Pacific 49 553 1 711 830 87.1 720 30 357 1.5
Philippines 25 473 616 611 562.7 301 12 766 11.6 Community transmission
Malaysia 10 632 322 409 996.1 40 1 206 3.7 Clusters of cases
Japan 7 917 446 873 353.3 333 8 560 6.8 Clusters of cases
Republic of Korea 3 164 95 635 186.5 35 1 669 3.3 Clusters of cases
Mongolia 672 3 833 116.9 2 4 0.1 Clusters of cases
Papua New Guinea 590 2 173 24.3 5 21 0.2 Community transmission
Cambodia 318 1 305 7.8 1 1 0.0 Sporadic cases
China 269 102 333 7.0 1 4 849 0.3 Clusters of cases
Australia 82 29 112 114.2 0 909 3.6 Clusters of cases
Singapore 68 60 088 1 027.1 1 30 0.5 Sporadic cases
Viet Nam 44 2 553 2.6 0 35 0.0 Clusters of cases
New Zealand 24 2 067 42.9 0 26 0.5 Clusters of cases
Brunei Darussalam 3 192 43.9 0 3 0.7 Sporadic cases
Fiji 3 66 7.4 0 2 0.2 Sporadic cases
 Cumulative cases Cumulative
New cases New
Reporting Cumulative per 100 Cumulative deaths per 100 Transmission
in last 7 deaths in
Country/Territory/Areai cases thousand deaths thousand classificationii
days last 7 days
population population
Lao People's Democratic Republic 2 49 0.7 0 0 0.0 Sporadic cases
Solomon Islands 0 18 2.6 0 0 0.0 No cases
Territoriesiii
Wallis and Futuna 166 176 1 565.0 0 0 0.0 Sporadic cases
French Polynesia 68 18 527 6 595.4 1 141 50.2 Sporadic cases
New Caledonia 33 91 31.9 0 0 0.0 Sporadic cases
Guam 18 7 558 4 478.2 0 133 78.8 Clusters of cases
Northern Mariana Islands
5 150 260.6 0 2 3.5 Pending
(Commonwealth of the)
Vanuatu 2 3 1.0 0 0 0.0 No cases
Marshall Islands 0 4 6.8 0 0 0.0 No cases
Samoa 0 4 2.0 0 0 0.0 No cases
Global 3 035 703 119 218 587 1 529.4 58 672 2 642 673 33.9
*See Annex: Data, table and figure notes
Annex 2. List of countries/territories/areas reporting variants of concern as of 16 March 2021**

501Y.v2 P.1 VOC 202012/01 501Y.v2 P.1 VOC 202012/01

Country/Territory/Area Country/Territory/Area
(B.1.351) (B.1.1.28) (B.1.1.7) (B.1.351) (B.1.1.28) (B.1.1.7)
Albania Costa Rica Verified Verified
Angola Verified Verified Croatia Not Verified Verified
Argentina Verified Verified Cuba Verified
Aruba Verified Curaçao Verified
Australia Verified Verified Cyprus Verified
Austria Verified Verified Czechia Not Verified Verified
Bahrain Democratic Republic of the
Not Verified
Congo
Bangladesh Verified
Denmark Verified Verified Verified
Barbados Verified
Dominican Republic Verified
Belarus
Ecuador Verified
Belgium Verified Verified Verified
Estonia Not Verified Verified
Belize Verified
Faroe Islands Verified
Bonaire Verified
Finland Verified Verified Verified
Bosnia and Herzegovina Not Verified
France Verified Verified Verified
Botswana Verified
French Guiana Verified Verified
Brazil Verified Verified
French Polynesia Verified
Brunei Darussalam Verified
Gambia Verified
Bulgaria Verified
Georgia Verified
Cabo Verde Verified
Germany Verified Verified Verified
Cambodia Verified
Ghana Verified Verified
Cameroon Verified
Gibraltar Not Verified
Canada Verified Verified Verified
Greece Verified Verified
Cayman Islands Verified
Guadeloupe Verified
Chile Verified Verified
Hungary Not Verified Verified
China Verified Not Verified Verified
Iceland Verified
Colombia Verified
India Verified Verified Verified
Comoros Verified
Indonesia Verified
 501Y.v2 P.1 VOC 202012/01 501Y.v2 P.1 VOC 202012/01
Country/Territory/Area Country/Territory/Area
(B.1.351) (B.1.1.28) (B.1.1.7) (B.1.351) (B.1.1.28) (B.1.1.7)
Iran (Islamic Republic of) Verified Netherlands Verified Verified Verified
Iraq Verified New Caledonia
Ireland Verified Not Verified Verified New Zealand Verified Verified
Israel Verified Verified Nigeria Verified
Italy Not Verified Verified Verified North Macedonia Verified
Jamaica Verified Norway Verified Verified
Japan Verified Verified Verified occupied Palestinian territory Verified
Jordan Verified Oman Verified
Kenya Verified Pakistan Verified
Kosovo[1] Verified Panama Verified
Kuwait Verified Peru Verified Verified
Latvia Verified Philippines Verified Verified Verified
Lebanon Verified Poland Not Verified Verified
Libya Verified Portugal Verified Not Verified Verified
Liechtenstein Verified Puerto Rico Verified
Lithuania Verified Republic of Korea Verified Verified Verified
Luxembourg Verified Verified Republic of Moldova
Malawi Verified Réunion Verified Verified Verified
Malaysia Verified Romania Verified Verified Verified
Malta Not Verified Verified Russian Federation Verified
Martinique Verified Saint Barthélemy Verified
Mayotte Verified Verified Saint Lucia Verified
Mexico Verified Verified Saint Martin Verified
Monaco Saudi Arabia Verified
Montenegro Verified Senegal Verified
Morocco Verified Serbia Verified
Mozambique Verified Singapore Verified
Namibia Verified Slovakia Not Verified Verified
Nepal Verified Slovenia Verified Verified
 501Y.v2 P.1 VOC 202012/01 501Y.v2 P.1 VOC 202012/01
Country/Territory/Area Country/Territory/Area
(B.1.351) (B.1.1.28) (B.1.1.7) (B.1.351) (B.1.1.28) (B.1.1.7)
South Africa Verified Verified Ukraine Not Verified
Spain Verified Verified Verified United Arab Emirates Verified Verified Verified
Sri Lanka Verified United Republic of Tanzania Not Verified
Sweden Verified Not Verified Verified United States of America Verified Verified Verified
Switzerland Verified Not Verified Verified Uruguay Verified
Thailand Verified Verified Uzbekistan Verified
The United Kingdom Verified Verified Verified Venezuela (Bolivarian Republic
Verified
of)
Trinidad and Tobago Verified
Viet Nam Verified Verified
Tunisia Verified
Wallis and Futuna
Turkey Not Verified Not Verified Verified
Zambia Verified
Turks and Caicos Islands Verified
Zimbabwe Verified

**See Annex : Data, table and figure notes

Annex 3. Data, table and figure notes

Data presented are based on official laboratory-confirmed COVID-19 case and deaths reported to WHO by
country/territories/areas, largely based upon WHO case definitions and surveillance guidance. While steps are
taken to ensure accuracy and reliability, all data are subject to continuous verification and change, and caution
must be taken when interpreting these data as several factors influence the counts presented, with variable
underestimation of true case and death incidence, and variable delays to reflecting these data at global level. Case
detection, inclusion criteria, testing strategies, reporting practices, and data cut-off and lag times differ between
countries/territories/areas. A small number of countries/territories/areas report combined probable and
laboratory-confirmed cases. Differences are to be expected between information products published by WHO,
national public health authorities, and other sources. Due to public health authorities conducting data
reconciliation exercises which remove large numbers of cases or deaths from their total counts, negative numbers
may be displayed in the new cases/deaths columns as appropriate. When additional details become available that
allow the subtractions to be suitably apportioned to previous days, graphics will be updated accordingly. A record
of historic data adjustment made is available upon request by emailing epi-data-support@who.int. Please specify
the country(ies) of interest, time period(s), and purpose of the request/intended usage. Prior situation reports
will not be edited; see covid19.who.int for the most up-to-date data. Global totals include 745 cases and 13
deaths reported from international conveyances.

The designations employed, and the presentation of these materials do not imply the expression of any
opinion whatsoever on the part of WHO concerning the legal status of any country, territory or area or of its
authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps
represent approximate border lines for which there may not yet be full agreement. Countries, territories and
areas are arranged under the administering WHO region. The mention of specific companies or of certain
manufacturers’ products does not imply that they are endorsed or recommended by WHO in preference to
others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary
products are distinguished by initial capital letters.

[1]
All references to Kosovo should be understood to be in the context of the United Nations Security Council
resolution 1244 (1999). In the map, number of cases of Serbia and Kosovo (UNSCR 1244, 1999) have been
aggregated for visualization purposes.

i
Excludes countries, territories, and areas that have never reported a confirmed COVID-19 case (Annex 1), or the
detection of a variant of concern (Annex 2).

ii
Transmission classification is based on a process of country/territory/area self-reporting. Classifications are
reviewed on a weekly basis and may be revised as new information becomes available. Differing degrees of
transmission may be present within countries/territories/areas. For further information, please see:
Considerations for implementing and adjusting public health and social measures in the context of COVID-19:

• No (active) cases: No new cases detected for at least 28 days (two times the maximum incubation period), in
the presence of a robust surveillance system. This implies a near-zero risk of infection for the general
population.
• Imported / Sporadic cases: Cases detected in the past 14 days are all imported, sporadic (e.g., laboratory
acquired or zoonotic) or are all linked to imported/sporadic cases, and there are no clear signals of further
locally acquired transmission. This implies minimal risk of infection for the general population.
• Clusters of cases: Cases detected in the past 14 days are predominantly limited to well-defined clusters that
are not directly linked to imported cases, but which are all linked by time, geographic location and common
exposures. It is assumed that there are a number of unidentified cases in the area. This implies a low risk of
infection to others in the wider community if exposure to these clusters is avoided.
• Community transmission: Which encompasses a range of levels from low to very high incidence, as described
below and informed by a series of indicators described in the aforementioned guidance. As these
subcategorization are not currently collated at the global level, but rather intended for use by national and
sub-national public health authorities for local decision-making, community transmission has not been
disaggregated in this information product.
o CT1: Low incidence of locally acquired, widely dispersed cases detected in the past 14 days, with many of
the cases not linked to specific clusters; transmission may be focused in certain population sub-groups.
Low risk of infection for the general population.
o CT2: Moderate incidence of locally acquired, widely dispersed cases detected in the past 14 days;
transmission less focused in certain population sub-groups. Moderate risk of infection for the general
population.
o CT3: High incidence of locally acquired, widely dispersed cases in the past 14 days; transmission
widespread and not focused in population sub-groups. High risk of infection for the general population.
o CT4: Very high incidence of locally acquired, widely dispersed cases in the past 14 days. Very high risk of
infection for the general population.
• Pending: transmission classification has not been reported to WHO.

iii
“Territories” include territories, areas, overseas dependencies and other jurisdictions of similar status.